Key result
CalDAG-GEFI deficiency in mice virtually abolished arterial thrombosis while maintaining hemostatic function, suggesting a better safety profile than P2Y12 inhibitors like clopidogrel.
Why the study?
Does genetic deletion of CalDAG-GEFI reduce thrombosis and preserve hemostasis compared to clopidogrel in mice?
Population
Mice (CalDAG-GEFI mice, wild-type mice, and mice with specific deletion of the C1-like domain of CalDAG-GEFI…
Comparison
Genetic deletion of CalDAG-GEFI or its C1-like… vs Wild-type mice treated with clopidogrel
Design
Preclinical
Authors
Loading...
Does not support clinical use of CalDAG-GEFI inhibitors; leaves open translation of thrombosis protection without bleeding to humans.
Does genetic deletion of CalDAG-GEFI reduce thrombosis and preserve hemostasis compared to clopidogrel in mice?
Inhibition of CalDAG-GEFI may provide strong protection from atherothrombotic complications with a better safety profile (less bleeding) than P2Y12 inhibitors like clopidogrel.
Stolla et al. (2010) studied Thrombosis and hemostasis. CalDAG-GEFI deficiency/inhibition vs. Clopidogrel (P2Y12 inhibition) / wild-type was evaluated on Thrombus formation and hemostasis. CalDAG-GEFI deficiency in mice virtually abolished arterial thrombosis while maintaining hemostatic function, suggesting a better safety profile than P2Y12 inhibitors like clopidogrel.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: